Inhibitory short synthetic oligodeoxynucleotides and lupus

doi:10.1186/ar2726

Arthritis Research & Therapy

Volume 11
Issue 3

Viewing options:

Abstract
Full text
PDF (120KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Liu Z
Davidson A

on PubMed

Liu Z
Davidson A
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Editorial

Inhibitory short synthetic oligodeoxynucleotides and lupus

Zheng Liu¹ and Anne Davidson²

¹Department of Microbiology, Columbia University, New York, NY 10032

²Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA

author email corresponding author email

Arthritis Research & Therapy 2009, 11:116doi:10.1186/ar2726


Published:	26 June 2009

See related research by Lenert et al., http://arthritis-research.com/content/11/3/R79

Abstract

B cells and antigen-presenting cells express a group of intracellular Toll-like receptors (TLRs) that recognize nucleic acids and can be accessed only when apoptotic debris or immune complexes are internalized by B-cell receptors or Fc receptors. This results in rapid cell activation and release of inflammatory mediators that perpetuate the autoantibody response. TLR-7 and TLR-9 are required to generate autoantibodies to RNA and DNA, respectively. Synthetic oligodeoxynucleotides that inhibit the activity of these intracellular TLRs attenuate systemic lupus erythematosus in mouse models and may be of therapeutic benefit in human systemic lupus erythematosus.